ArticleCombinatorial chemistry & high throughput screening2026
Effects of Limb Remote Ischemic Conditioning and Asafoetida on Biochemical, Histological, and Neurological Parameters and Metabolic Gene Expression in Diabetic Rats.
Article in Combinatorial chemistry & high throughput screening, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes mellitus is a global metabolic disorder driven by insulin deficiency and hyperglycemia. Asafoetida (Ferula assa-foetida) exhibits antioxidant and antiinflammatory properties with potential hypoglycemic effects. Limb remote ischemic conditioning (LRIC) activates protective pathways, yet its antidiabetic efficacy remains uncertain. MATERIALS AND
methodsType 2 diabetes was induced in male Wistar rats (n=40) via a 60% high-fat diet (4 weeks) and streptozotocin (35 mg/kg, i.p.). Diabetic rats (>200 mg/dL glucose) were randomized (n=8): standard control, diabetic control, asafoetida (50 mg/kg/day, oral), LRIC (3×5-min hindlimb cycles daily), asafoetida + LRIC. After 8 weeks, glucose, lipids, liver enzymes, HbA1c, weight, intake, histology (liver/pancreas), muscle gene expression (adiponectin, GLUT4, insulin receptor, AMPK; RT-PCR), neuropathy (hot-plate), and memory (shuttle box) were assessed.
resultsAsafoetida and asafoetida + LRIC reduced glucose levels (-49%, -41%), lipids, liver enzymes, and HbA1c intake; increased weight and HDL (p < 0.05 vs. diabetic). LRIC alone showed no effect. Histology improved (less congestion, necrosis); gene expression upregulated (p<0.05). Pain latency and memory (step latency, light time) were enhanced in the asafoetida groups (p < 0.05), not in the LRIC. DISCUSSION: Asafoetida improved metabolic, histological, and neurological outcomes via insulin signaling. LRIC failed, contradicting protective claims. Limitations include a single asafoetida dose without titration, brief LRIC cycles that may be inadequate in hyperglycemia, the absence of mechanistic probes, a male-only cohort, and the lack of long-term safety or human relevance. Future dose-ranging, sex-inclusive, mediator-focused, chronic studies needed.
conclusionIn conclusion, asafoetida improved glycemic control, lipid metabolism, and diabetes- related tissue damage while also enhancing neurological function in diabetic rats. In contrast, LRIC showed no significant protective effects. These findings suggest that asafoetida may be a promising candidate for the management of type 2 diabetes and its associated complications.
Indexed as
Identifiers
40947686What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.